Various mutations of p53 are associated with human cancers and the onset of MDR in a broad field of solid and haematological malignancies (Ogretmen and Safa, 1997; Schmitt and Lowe, 1999; Smith et al, 2003; Norbury and Zhivotovsky, 2004; Pommier et al, 2004; Kim, 2005; Steele and Lane, 2005). Here, TP53 is linked to cancer.